| Muscular Dystrophy, Duchenne
Exondys 51 vs Vyondys 53
Side-by-side clinical, coverage, and cost comparison for muscular dystrophy, duchenne.Deep comparison between: Exondys 51 vs Vyondys 53 with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVyondys 53 has a higher rate of injection site reactions vs Exondys 51 based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vyondys 53 but not Exondys 51, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Exondys 51
Vyondys 53
At A Glance
IV infusion
Once weekly
Antisense oligonucleotide (exon 51 skipper)
IV infusion
Once weekly
Exon 53 skipping antisense oligonucleotide
Indications
- Muscular Dystrophy, Duchenne
- Muscular Dystrophy, Duchenne
Dosing
Muscular Dystrophy, Duchenne 30 mg/kg once weekly as a 35 to 60 minute IV infusion via an in-line 0.2 micron filter.
Muscular Dystrophy, Duchenne 30 mg/kg IV infusion once weekly over 35 to 60 minutes via an in-line 0.2 micron filter.
Contraindications
—
- Serious hypersensitivity reaction to golodirsen or any inactive ingredient in VYONDYS 53
Adverse Reactions
Most common (>=35%) balance disorder, vomiting
Postmarketing bronchospasm, cyanosis of the lips, malaise, pyrexia, flushing, protein urine present, dehydration
Most common (>=20%) Headache, pyrexia, fall, abdominal pain, nasopharyngitis, cough, vomiting, nausea
Serious Hypersensitivity reactions
Postmarketing Anaphylaxis
Pharmacology
Eteplirsen is an antisense phosphorodiamidate morpholino oligomer that binds to exon 51 of dystrophin pre-mRNA, causing exon skipping during mRNA processing to allow production of an internally truncated dystrophin protein in patients with DMD mutations amenable to exon 51 skipping.
Golodirsen is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass that binds to exon 53 of dystrophin pre-mRNA, inducing exon 53 exclusion during mRNA processing to allow production of an internally truncated dystrophin protein in patients with DMD gene mutations amenable to exon 53 skipping.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Exondys 51
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
Vyondys 53
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Exondys 51
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vyondys 53
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Exondys 51
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Vyondys 53
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Duchenne Muscular Dystrophy
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Exondys 51View full Exondys 51 profile
Vyondys 53View full Vyondys 53 profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.